KTN-3379

N/A

Report date: 2023/04/04 20:00:35

Base Information

Drug NameKTN-3379
Drug Alias NameKTN-3379CDX-3379
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsThyroid NeoplasmsSquamous Cell Carcinoma of Head and NeckNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelldex Therapeutics
Active IndicationsN/A
Inactive IndicationsThyroid NeoplasmsSquamous Cell Carcinoma of Head and NeckNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A